

## Update to OPASt/GNFS Ordering Procedures in Dx

Date: December 11<sup>th</sup>, 2025

---

Effective Date: December 15<sup>th</sup>, 2025

The Molecular Diagnostic Laboratory is implementing a **change to the ordering process for OPASt (Oncogenic Precision Assay Solid Tumor NGS) and GNFS (Lung Cancer Gene Fusion Panel) in Dx**. This update aims to optimize testing pathways while ensuring appropriate patient care.

Going forward, when OPASt/GNFS is ordered in Dx using the combined dropdown option, the testing will follow a streamlined reflex pathway:

- OPASt ngs panel is performed
- GNFS reflex logic
  - The fusion assay (GNFS) will be performed only if no pathogenic or likely pathogenic variants are detected by OPASt. This pathway does not require additional action from the requestor.
  - If a Tier I or II variant is detected, the lab will cancel the GNFS assay. A cancellation report stating that “GNFS test was not indicated based upon the OPASt result” will be issued.

We understand that clinical situations can vary. **If there is a medical necessity to proceed with GNFS regardless of the OPASt result, you may still order both OPASt and GNFS as separate line items.** In such cases, the GNFS will be performed even if OPASt yields a positive result. We believe this updated process will enhance efficiency in our diagnostic workflow.

For any questions, please contact:

Allison Cox, Ph.D.  
Interim Director of the Molecular Diagnostic Laboratory, UR Medicine Labs  
Phone: (585) 758-0456  
Email: [Allison\\_Cox@URMC.Rochester.edu](mailto:Allison_Cox@URMC.Rochester.edu)

Paige Elliott  
Supervisor, Molecular Diagnostic Laboratory  
Phone: (585) 275-2709  
Email: [Paige\\_Elliott@urmc.rochester.edu](mailto:Paige_Elliott@urmc.rochester.edu)